Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00980785 · ClinicalTrials.gov registry record · Phase 4
Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's
A Phase 4 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT00980785 is a Phase 4 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 14 participants.
The verdict
NCT00980785, a Phase 4 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
Angiotensin converting enzyme inhibitors (ACE-I) are a group of blood pressure-lowering medicines. Some studies suggest that ACE-I, such as ramipril, may help prevent Alzheimer's disease (AD). The purpose of the research is to see how ramipril affects a substance in the body called beta-amyloid. Beta-amyloid is found in the brain and in the liquid around the brain and spinal cord. High amounts of beta-amyloid may be associated with a greater risk of getting Alzheimer's disease. This study will see if ramipril can lower the amount of beta-amyloid in the spinal fluid. This study will also see if ramipril affects blood vessel function and memory and thinking. The investigators hope that future studies will show whether ramipril might prevent memory loss and decrease the chance of developing Alzheimer's disease.
Interventions
- DRUG Placebo
- DRUG Ramipril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-04-09 |
| Est. Completion | 2011-07-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00980785
The ClinicalTrials.gov registry entry for NCT00980785 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00980785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00980785 about?
NCT00980785 is a clinical study titled "Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's". Angiotensin converting enzyme inhibitors (ACE-I) are a group of blood pressure-lowering medicines. Some studies suggest that ACE-I, such as ramipril, may help prevent Alzheimer's disease (AD). The purpose of the research is to see how ramipril affects a substance in the body called beta-amyloid. Bet...
What is the current status of trial NCT00980785?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2009-04-09. Estimated completion is 2011-07-26.
What interventions are being tested in trial NCT00980785?
The interventions under investigation include: Placebo (DRUG), Ramipril (DRUG).
Who is sponsoring clinical trial NCT00980785?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.